The useful question is what changes for users, developers or buyers, and whether the announcement stays industry context or becomes something people can actually use.

The U.S. Food and Drug Administration granted De Novo marketing authorization to Johnson & Johnson’s OTTAVA™ Robotic Surgical System on July 22, 2026, marking the first table-integrated soft tissue robotic system authorized in the country. The approval covers procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, and appendectomy, among others. Johnson & Johnson plans an initial commercial launch with select U.S. customers while expanding indications and regulatory approvals over time.

Johnson & Johnson described OTTAVA as purpose-built to integrate into operating rooms with automated features, next-generation instruments, and an open digital ecosystem. The system is designed to enhance operating room efficiency, streamline clinical workflows, and improve access to robotic-assisted surgery. A U.S. clinical trial for inguinal hernia procedures using OTTAVA is currently underway.

Company executives emphasized OTTAVA’s role in addressing variability in surgical outcomes by integrating data and insights across the surgical ecosystem. The system’s architecture and connectivity aim to support surgeon judgment and improve patient outcomes. Johnson & Johnson highlighted its commitment to advancing surgical care through innovation and collaboration with healthcare providers.

Johnson & Johnson will host an investor conference call on August 3, 2026, at 8:00 a.m. Eastern Time to discuss the announcement. The company’s MedTech division focuses on advancing surgical solutions, including robotics, digital tools, and instruments, to address complex health challenges across multiple medical specialties.